An observational study was conducted in 201rheumatoid arthritis patients aged ≥ 18 years. Clinical response and DMARD use were monitored by laboratory parameters, objective signs and symptoms and assessment of patient health related quality of life questionnaire. The early use of DMARDs highlighted a decline in the severity of the disease. Treatment response was assessed by use of disease activity score of 28 joints (DAS28) using Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP) and Short Form of Arthritis Impact Measurement Scale 2 (AIMS2SF). The commonly reported adverse effects included dyspepsia and hair loss which were manageable. The use of Combination DMARD therapy proved to be safe and efficacious in treating rheumatoid arthritis patients which are unaffected by non-steroidal anti-inflammatory drugs and analgesics.
